(PDF) Pemetrexed Had Significantly Better Clinical Efficacy

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

OncoTargets and Therapy - New Zealand

doi 10.2147/ott.s100164

Full Text

Open PDF

Abstract

Available in full text

Date

March 1, 2016

Authors

Publisher

Informa UK Limited

Related search

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

International Journal of Cancer

Cancer Research

Oncology

2017

English

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

P3.01-47 Clinical Characteristics and Outcome for Patients With Advanced Lung Adenocarcinoma Treated With First-Line Pemetrexed Plus Platinum

Journal of Thoracic Oncology

English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

Journal of Thoracic Oncology

English

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

Journal of Thoracic Oncology

English

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

English

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Journal of Thoracic Oncology

English

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

English

Amanote Research

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

OncoTargets and Therapy - New Zealand

doi 10.2147/ott.s100164

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

P3.01-47 Clinical Characteristics and Outcome for Patients With Advanced Lung Adenocarcinoma Treated With First-Line Pemetrexed Plus Platinum

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma